EmbryoPhenomics is a University of Plymouth research group, founded by Dr Oliver Tills, the Park’s Researcher in Residence.
The team are developing the next generation of technologies for capturing the dynamic process of embryonic development in aquatic animals, applying new technology to some of the most pressing challenges in biology.
EmbryoPhenomics are at the forefront of next-generation technologies for measuring animals’ responses to their environment during their embryonic development. They bring together robotics, 3D printing and AI to revolutionise the study of animals at the earliest stages of life. This innovative approach aims to move away from manual microscope-based observations, and embrace automation.
Re:Cognition Health is delivering the global clinical trial for Lecanemab, a new Alzheimer’s drug which could be a breakthrough for future generations. Re:Cognition Health is one of the world’s leading clinics for delivering international clinical trials for Alzheimer’s and other causes of dementia.